NCT06441890View on ClinicalTrials.gov

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Breast CancerHER2-positive Breast Cancer
Interventions
DRUG

Paclitaxel

80mg/m2 IV D1, 8, 15

DRUG

Nab-paclitaxel

125mg/m2 IV D1, 8, 15

DRUG

Docetaxel

75mg/m2 IV D1

DRUG

Trastuzumab

8mg/kg loading, then 6mg/kg IV/SQ D1

DRUG

Pertuzumab

840 mg loading, then 420mg IV/SQ D1

Trial Locations (1)

60612

RECRUITING

University of Illinois, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER